MASL is developed by Rowan University.

What development phase is MASL in?

MASL is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

MASL

Rowan University · FDA-approved active Small molecule Quality 4/100

At a glance

Generic name	MASL
Also known as	Maackia amurensis seed lectin
Sponsor	Rowan University
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Using MASL to Combat Oral Cancer (EARLY_PHASE1)
The Effect of Acute High Altitude Exposure on Rescuer Performance and Patient Care (NA)
The Pre-acclimatization Augmented Extreme Altitude Expedition (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MASL CI brief — competitive landscape report
MASL updates RSS · CI watch RSS
Rowan University portfolio CI